361 related articles for article (PubMed ID: 36009418)
21. Adaptive responses of androgen receptor signaling in castration-resistant prostate cancer.
Perner S; Cronauer MV; Schrader AJ; Klocker H; Culig Z; Baniahmad A
Oncotarget; 2015 Nov; 6(34):35542-55. PubMed ID: 26325261
[TBL] [Abstract][Full Text] [Related]
22. MicroRNA Regulation of Androgen Receptor in Castration-Resistant Prostate Cancer: Premises, Promises, and Potentials.
Ebrahimi S; Hashemy SI; Sahebkar A; Aghaee Bakhtiari SH
Curr Mol Pharmacol; 2021 Oct; 14(4):559-569. PubMed ID: 33357209
[TBL] [Abstract][Full Text] [Related]
23. Understanding Mechanisms of Resistance in Metastatic Castration-resistant Prostate Cancer: The Role of the Androgen Receptor.
Tilki D; Schaeffer EM; Evans CP
Eur Urol Focus; 2016 Dec; 2(5):499-505. PubMed ID: 28723515
[TBL] [Abstract][Full Text] [Related]
24. Vav3 enhances androgen receptor splice variant activity and is critical for castration-resistant prostate cancer growth and survival.
Peacock SO; Fahrenholtz CD; Burnstein KL
Mol Endocrinol; 2012 Dec; 26(12):1967-79. PubMed ID: 23023561
[TBL] [Abstract][Full Text] [Related]
25. A novel AR translational regulator lncRNA LBCS inhibits castration resistance of prostate cancer.
Gu P; Chen X; Xie R; Xie W; Huang L; Dong W; Han J; Liu X; Shen J; Huang J; Lin T
Mol Cancer; 2019 Jun; 18(1):109. PubMed ID: 31221168
[TBL] [Abstract][Full Text] [Related]
26. Molecular model for neuroendocrine prostate cancer progression.
Chen R; Dong X; Gleave M
BJU Int; 2018 Oct; 122(4):560-570. PubMed ID: 29569310
[TBL] [Abstract][Full Text] [Related]
27. Blocking GRP/GRP-R signaling decreases expression of androgen receptor splice variants and inhibits tumor growth in castration-resistant prostate cancer.
Case TC; Merkel A; Ramirez-Solano M; Liu Q; Sterling JA; Jin R
Transl Oncol; 2021 Nov; 14(11):101213. PubMed ID: 34461557
[TBL] [Abstract][Full Text] [Related]
28. Recent advances in understanding hormonal therapy resistant prostate cancer.
Donkena KV; Yuan H; Young CY
Curr Cancer Drug Targets; 2010 Jun; 10(4):402-10. PubMed ID: 20464780
[TBL] [Abstract][Full Text] [Related]
29.
Fararjeh AS; Liu YN
Int J Mol Sci; 2019 Jun; 20(11):. PubMed ID: 31181727
[TBL] [Abstract][Full Text] [Related]
30. Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer.
Hu R; Lu C; Mostaghel EA; Yegnasubramanian S; Gurel M; Tannahill C; Edwards J; Isaacs WB; Nelson PS; Bluemn E; Plymate SR; Luo J
Cancer Res; 2012 Jul; 72(14):3457-62. PubMed ID: 22710436
[TBL] [Abstract][Full Text] [Related]
31. NDRG2 acts as a negative regulator downstream of androgen receptor and inhibits the growth of androgen-dependent and castration-resistant prostate cancer.
Yu C; Wu G; Li R; Gao L; Yang F; Zhao Y; Zhang J; Zhang R; Zhang J; Yao L; Yuan J; Li X
Cancer Biol Ther; 2015; 16(2):287-96. PubMed ID: 25756511
[TBL] [Abstract][Full Text] [Related]
32. Androgen Receptor-Dependent and -Independent Mechanisms Involved in Prostate Cancer Therapy Resistance.
Crona DJ; Whang YE
Cancers (Basel); 2017 Jun; 9(6):. PubMed ID: 28604629
[TBL] [Abstract][Full Text] [Related]
33. Downregulation of
Russo JW; Gao C; Bhasin SS; Voznesensky OS; Calagua C; Arai S; Nelson PS; Montgomery B; Mostaghel EA; Corey E; Taplin ME; Ye H; Bhasin M; Balk SP
Cancer Res; 2018 Nov; 78(22):6354-6362. PubMed ID: 30242112
[TBL] [Abstract][Full Text] [Related]
34. Role of Androgen Receptor in Prostate Cancer: A Review.
Fujita K; Nonomura N
World J Mens Health; 2019 Sep; 37(3):288-295. PubMed ID: 30209899
[TBL] [Abstract][Full Text] [Related]
35. Subgroups of Castration-resistant Prostate Cancer Bone Metastases Defined Through an Inverse Relationship Between Androgen Receptor Activity and Immune Response.
Ylitalo EB; Thysell E; Jernberg E; Lundholm M; Crnalic S; Egevad L; Stattin P; Widmark A; Bergh A; Wikström P
Eur Urol; 2017 May; 71(5):776-787. PubMed ID: 27497761
[TBL] [Abstract][Full Text] [Related]
36. Resetting the Bar of Castration Resistance - Understanding Androgen Dynamics in Therapy Resistance and Treatment Choice in Prostate Cancer.
Shore ND; Morgans AK; Ryan CJ
Clin Genitourin Cancer; 2021 Jun; 19(3):199-207. PubMed ID: 33129718
[TBL] [Abstract][Full Text] [Related]
37. RNA-binding protein DDX3 mediates posttranscriptional regulation of androgen receptor: A mechanism of castration resistance.
Vellky JE; McSweeney ST; Ricke EA; Ricke WA
Proc Natl Acad Sci U S A; 2020 Nov; 117(45):28092-28101. PubMed ID: 33106406
[TBL] [Abstract][Full Text] [Related]
38. Targeting the androgen receptor signaling pathway in advanced prostate cancer.
Chung C; Abboud K
Am J Health Syst Pharm; 2022 Jul; 79(15):1224-1235. PubMed ID: 35390118
[TBL] [Abstract][Full Text] [Related]
39. Strategies to Re-Sensitize Castration-Resistant Prostate Cancer to Antiandrogen Therapy.
Congregado Ruiz B; Rivero Belenchón I; Lendínez Cano G; Medina López RA
Biomedicines; 2023 Apr; 11(4):. PubMed ID: 37189723
[TBL] [Abstract][Full Text] [Related]
40. Androgen receptor cofactors in prostate cancer: potential therapeutic targets of castration-resistant prostate cancer.
Shiota M; Yokomizo A; Fujimoto N; Naito S
Curr Cancer Drug Targets; 2011 Sep; 11(7):870-81. PubMed ID: 21762076
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
